2024 Rome, Italy

I-043 Nils Bundgaard
Model informed dose projection for SAB-176 using a joint time-to-event modeling approach in high-risk (HR) patients infected with Influenza
Wednesday 10:20-11:50
I-044 Nils Bundgaard
Framework for Polyclonal Antibody Drug Development: Integrating Trial Data and Literature Models
Wednesday 10:20-11:50
I-045 Nils Bundgaard
Characterization of the population dose-exposure-efficacy relationships of vamorolone, a synthetic corticosteroid drug in the treatment of Duchenne Muscular Dystrophy (DMD)
Wednesday 10:20-11:50